# Altman Z-Score Analysis Report: Johnson & Johnson (JNJ)

---
## Introduction
This report provides a comprehensive, theory-informed financial health analysis of the selected company using the Altman Z-Score framework. It integrates quantitative diagnostics, turnaround management theory, and stakeholder recommendations, with all findings and recommendations grounded in referenced academic and industry sources. The analysis is generated by an expert LLM-driven pipeline, ensuring transparency, reproducibility, and robust source attribution.

**Author:** Fabio Correa

**Source Attribution:** This report and analysis pipeline are generated using the open-source Altman Z-Score Analysis project, available at [https://github.com/fabioc-aloha/Altman-Z-Score](https://github.com/fabioc-aloha/Altman-Z-Score).

**License:** This software is distributed under the Attribution Non-Commercial License (MIT-based). See the LICENSE file for details.

Disclaimer: The developer disclaims any responsibility for the accuracy, completeness, or consequences of the analysis and information provided by this software. All results are for informational purposes only and should not be relied upon for financial, investment, or legal decisions.
---

**Script Version:** v2.6

## Analysis Context and Z-Score Model Selection Criteria

- **Industry:** Pharmaceutical Preparations (SIC 2834)
- **Ticker:** JNJ
- **Public:** True
- **Emerging Market:** False
- **Maturity:** Mature Company
- **Model:** Original Z-Score (Public Manufacturing, 1968) (original)
- **Analysis Date:** 2025-06-02

## Z-Score Formula Used

Z = 1.20*X1 + 1.40*X2 + 3.30*X3 + 0.60*X4 + 1.00*X5
- X1 = (Current Assets - Current Liabilities) / Total Assets
- X2 = Retained Earnings / Total Assets
- X3 = EBIT / Total Assets
- X4 = Equity / Total Liabilities
- X5 = Sales / Total Assets

**Thresholds:**
- Safe Zone: > 2.99
- Grey Zone: > 1.81 and <= 2.99
- Distress Zone: <= 1.81



---

# Graphical View of the Z-Score Analysis


![Z-Score and Price Trend Chart](zscore_JNJ_trend.png)

*Figure: Z-Score and stock price trend for JNJ (image not available yet; will be generated after analysis)*


## Z-Score Component Table (by Quarter)
| Quarter   |    X1 |   X2 |   X3 |    X4 |   X5 |   Z-Score | Diagnostic   | Consistency Warning   |
|-----------|-------|------|------|-------|------|-----------|--------------|-----------------------|
| 2025 Q1   | 0.076 |    0 |    0 | 3.38  |    0 |     2.119 | Grey Zone    |                       |
| 2024 Q4   | 0.031 |    0 |    0 | 3.161 |    0 |     1.933 | Grey Zone    |                       |
| 2024 Q3   | 0.008 |    0 |    0 | 3.505 |    0 |     2.113 | Grey Zone    |                       |
| 2024 Q2   | 0.021 |    0 |    0 | 3.109 |    0 |     1.891 | Grey Zone    |                       |
| 2024 Q1   | 0.048 |    0 |    0 | 3.587 |    0 |     2.21  | Grey Zone    |                       |
# Altman Z-Score Analysis Report: Johnson & Johnson (JNJ)

---
## Company Profile
Johnson & Johnson (JNJ) is a leading multinational corporation primarily engaged in the development, manufacturing, and marketing of a broad range of healthcare products. The company operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. JNJ competes with other major players in the pharmaceutical and healthcare industry, including Pfizer, Merck, and Abbott Laboratories. Its diverse product portfolio includes over-the-counter medications, surgical devices, and innovative pharmaceuticals, positioning it as a key player in the global healthcare market.

Recent financial analysis indicates that JNJ is currently situated in the **Grey Zone** of the Altman Z-Score framework, with a Z-Score of 2.119. This suggests a moderate risk level, indicating that while the company is not in immediate financial distress, it faces challenges that require strategic attention to ensure long-term stability and growth.

## 1. Diagnostic Evaluation of Financial Health
### Liquidity
JNJ's liquidity position, as indicated by the X1 component (Current Assets - Current Liabilities) / Total Assets, shows a slight increase over the past quarters, reflecting a cautious approach to managing short-term obligations. However, the low values suggest that liquidity could be a concern if not addressed.

### Profitability
The profitability metrics, particularly the X3 component (EBIT / Total Assets), indicate that JNJ has been struggling to generate sufficient earnings relative to its asset base. This trend is concerning and may impact investor confidence if not reversed.

### Capital Efficiency
The X2 component (Retained Earnings / Total Assets) remains at zero, indicating that JNJ has not retained earnings effectively, which could hinder future growth and investment opportunities.

### Leverage
JNJ's leverage, as measured by the X4 component (Equity / Total Liabilities), is strong, with a value of 3.38, suggesting that the company is well-capitalized and has a solid equity base relative to its liabilities. This provides a buffer against financial distress.

### Z-Score Trajectory
The Z-Score trajectory indicates fluctuations within the Grey Zone over the past year, with the most recent score of 2.119 showing a slight improvement from previous quarters. However, the overall trend suggests that JNJ must implement strategic initiatives to enhance its financial stability and move towards the Safe Zone.

---

## 2. Turnaround & Renewal Theory Application (Risk-Tailored)
Given JNJ's current position in the Grey Zone, the company should adopt a balanced approach that emphasizes both cost containment and strategic investments in core differentiators. 

### Phased Response
- **Cost Containment**: Implement measures to reduce operational costs without compromising product quality or innovation.
- **Strategic Investments**: Focus on R&D for new pharmaceuticals and medical devices that align with market needs and consumer trends.

### Theoretical Frameworks
- **Hofer (1980)**: Emphasizes the importance of sequencing turnaround strategies, suggesting that JNJ should prioritize immediate cost reductions followed by strategic investments.
- **Bibeault (1999)**: Highlights the need for identifying causes of failure; JNJ should analyze its profitability issues and address operational inefficiencies.
- **Hoskisson et al. (2004)**: Advocates for strategic restructuring; JNJ may consider divesting underperforming segments to reallocate resources effectively.
- **Freeman (1984)**: Stakeholder alignment is crucial; JNJ should engage with stakeholders to ensure that their interests are considered in strategic decisions.

---

## 3. Internal Stakeholder Recommendations (Tailored Table)

| Title         | Responsibilities                                   | Recommended Actions (Cited)                           |
|---------------|---------------------------------------------------|------------------------------------------------------|
| CEO           | Overall strategic direction                        | Lead cost containment initiatives and strategic investments. |
| CFO           | Financial management and reporting                 | Enhance liquidity management and monitor cash flows closely. |
| CMO           | Marketing and product strategy                     | Focus on promoting innovative products and enhancing brand loyalty. |
| Board         | Governance and oversight                           | Ensure alignment of strategic initiatives with long-term goals. |
| Employees     | Operational execution                              | Foster a culture of innovation and efficiency.       |
| Shareholders  | Investment and returns                             | Communicate transparently about financial strategies and performance. |
| Creditors     | Financial support and risk management              | Maintain open lines of communication regarding financial health. |
| Customers     | Product satisfaction and loyalty                   | Engage in feedback loops to improve product offerings. |
| Partners      | Collaborative opportunities                        | Explore partnerships for R&D and market expansion.   |

---

## 4. Communication, Marketing & Execution Strategy
### Internal and External Communication Plans
- **Internal**: Regular updates on financial performance and strategic initiatives to maintain employee morale and engagement.
- **External**: Transparent communication with investors and stakeholders regarding financial health and strategic direction.

### Milestones and Timelines
- **1–3 Months**: Implement cost containment measures; communicate changes to stakeholders.
- **4–6 Months**: Launch targeted marketing campaigns for new products; assess initial impacts on sales.
- **7–12 Months**: Review financial performance; adjust strategies as necessary based on market feedback.
- **13–18 Months**: Evaluate overall strategic effectiveness and stakeholder satisfaction.

### Marketing Tactics
- Focus on innovation campaigns to restore investor confidence and highlight new product developments.

---

## 5. Plain-Language Justification & Citation
The recommendations provided are grounded in empirical data and established theories. For instance, the emphasis on cost containment aligns with Bibeault's (1999) findings on recovery stages, while the focus on stakeholder engagement is supported by Freeman's (1984) stakeholder theory. These actions are tailored to JNJ's current financial health, ensuring that they are relevant and actionable.

---

## 6. Investor Recommendation (Risk-Aware)
**Recommendation**: **Hold**. While JNJ is currently in the Grey Zone, there are opportunities for improvement through strategic initiatives. Investors should monitor the company's progress closely.

> “This is not financial advice—consult your financial advisor.”

---

## 7. External Stakeholder Bargaining Power (Table)

| Stakeholder Name / Type | Nature of Bargaining Power | Degree of Influence | Brief Rationale (Cited) |
|-------------------------|----------------------------|---------------------|-------------------------|
| Investors               | Financial support          | High                | Investors are critical for funding and can influence strategic direction (Freeman, 1984). |
| Suppliers               | Input costs               | Medium              | Suppliers can impact production costs and availability. |
| Regulators              | Compliance requirements    | High                | Regulatory bodies have significant influence over operational practices. |
| Customers               | Market demand              | High                | Customer preferences directly affect sales and product development. |
| Competitors             | Market competition         | Medium              | Competitors influence market positioning and pricing strategies. |

---

## 8. Mandatory Disclaimer (Must Appear at End)

```
---
**Disclaimer:**
Generative AI is not a financial advisor and can make mistakes. Consult your financial advisor before making investment decisions.
- **LLM Model used:** [OpenAI o4-mini]
- **Knowledge cut-off:** [October 2023]
- **Internet search:** [no]
- **Real-time data:** [no]
---
```

---

## 9. References and Data Sources

```
---
### References and Data Sources
- **Financials:** SEC EDGAR/XBRL filings; Yahoo Finance; company quarterly/annual reports.
- **Market Data:** Yahoo Finance historical prices.
- **Computation:** Altman Z-Score calculations following Altman (1968) with robust error handling.
- **Source Attribution:** Open-source Altman Z-Score Analysis project (https://github.com/fabioc-aloha/Altman-Z-Score). Author: Fabio Correa.
- **Theoretical Frameworks:** 
  - Altman, E. I. (1968). “Financial Ratios, Discriminant Analysis and the Prediction of Corporate Bankruptcy.” *Journal of Finance*, 23(4), 589–609.
  - Hofer, C. W. (1980). *Turnaround Strategies.*
  - Bibeault, D. B. (1999). *Corporate Turnaround.*
  - Hoskisson, R. E., White, R. E., & Johnson, R. A. (2004). *Corporate Restructuring.*
  - Freeman, R. E. (1984). *Strategic Management: A Stakeholder Approach.*
  - [Include additional used sources here]
---
```



---

# Appendix

## Raw Data Field Mapping Table (by Quarter)
| Quarter   | Canonical Field   | Mapped Raw Field   | Value (USD millions)   |
|-----------|-------------------|--------------------|------------------------|
| ---       | ---               | ---                | ---                    |
| ---       | ---               | ---                | ---                    |
| ---       | ---               | ---                | ---                    |
| ---       | ---               | ---                | ---                    |

All values are shown in millions of USD as reported by the data source.

